Asia Pacific Preclinical Imaging Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 264,195.80 Thousand |
 Taille du marché (année de prévision) |
USD 396,436.69 Thousand |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché de l'imagerie préclinique en Asie-Pacifique, par produit (systèmes et services), réactifs (réactifs d'imagerie optique préclinique, réactifs d'imagerie nucléaire préclinique, agents de contraste IRM préclinique, agents de contraste échographiques précliniques et agents de contraste CT préclinique), application (recherche et développement, découverte de médicaments, biodistribution, détection de cellules cancéreuses, biomarqueurs et autres), utilisateur final (organisme de recherche sous contrat, sociétés pharmaceutiques et biotechnologiques, instituts de recherche universitaires et gouvernementaux, centre de diagnostic et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché de l'imagerie préclinique en Asie-Pacifique
Le marché de l'imagerie préclinique de la région Asie-Pacifique est l'industrie impliquée dans la fourniture de solutions et de technologies d'imagerie pour mener des recherches et des expérimentations sur des animaux (généralement des rongeurs) au stade préclinique du développement de médicaments et de la recherche médicale. Ces techniques d'imagerie sont essentielles pour évaluer la sécurité et l'efficacité des candidats médicaments potentiels et des traitements médicaux avant qu'ils ne passent aux essais cliniques impliquant des sujets humains. L'imagerie préclinique permet aux chercheurs et aux sociétés pharmaceutiques d'évaluer les effets des candidats médicaments sur les organismes vivants avant de passer aux essais sur l'homme. Cela permet d'identifier les problèmes potentiels, d'optimiser les schémas posologiques et de réduire le risque d'effets indésirables aux stades ultérieurs.
Data Bridge Market Research analyse que le marché de l'imagerie préclinique en Asie-Pacifique devrait atteindre la valeur de 396 436,69 milliers USD d'ici 2030, contre 264 195,80 milliers USD en 2022, à un TCAC de 5,5 % au cours de la période de prévision.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains |
|
Segments couverts |
Produit (systèmes et services), réactifs (réactifs d'imagerie optique préclinique, réactifs d'imagerie nucléaire préclinique, agents de contraste IRM préclinique, agents de contraste échographiques précliniques et agents de contraste CT préclinique), application (recherche et développement, découverte de médicaments, biodistribution, détection de cellules cancéreuses, biomarqueurs et autres), utilisateur final (organisme de recherche sous contrat, sociétés pharmaceutiques et biotechnologiques, instituts de recherche universitaires et gouvernementaux, centre de diagnostic et autres) |
|
Pays couverts |
Japon, Chine, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
PerkinElmer Inc., FUJIFILM Visualsonics, Inc (une filiale de FUJIFILM Corporation), Bruker, Hologic, Inc., ZEISS Group, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd., LI-COR, Inc., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, AI4R et entre autres |
Définition du marché
Preclinical imaging is the use of various imaging techniques and technologies to visualize and study biological processes, diseases, and drug responses in animal models before they are tested in humans. It involves the non-invasive imaging of animals, typically rodents, such as mice and rats, to gain insights into the underlying mechanisms of diseases and to evaluate the efficacy and safety of potential therapies.
Asia-Pacific Preclinical Imaging Market Dynamics
Drivers
- Increasing Technological Advancement in the Field of Imaging
Technology advancement in the field of imaging is playing a crucial role in driving the growth of the Asia-Pacific preclinical imaging market. Modern imaging technologies, such as high-resolution magnetic resonance imaging (MRI), micro-computed tomography (micro-CT), and advanced ultrasound provide researchers with clearer and more detailed images of biological structures.
Furthermore, there have been significant improvements in image analysis and data processing algorithms. Advanced software tools and machine learning algorithms enable researchers to extract quantitative data from images, automate image processing tasks, and improve the accuracy and efficiency of data analysis. These advancements save time and enhance the reproducibility and reliability of preclinical studies.
- Increasing Number of Investments and Funding in Research and Development
The increasing number of investments and funding in research and development (R&D) is a significant driver of the growth of the Asia-Pacific preclinical imaging market. Organizations are allocating substantial resources to advance imaging technologies and support innovative research initiatives as the importance of preclinical imaging in drug discovery and development becomes more evident.
Investments and funding in R&D enable the development of novel preclinical imaging modalities and techniques. This financial support facilitates the improvement of imaging systems, software, and hardware, leading to enhanced image quality, resolution, and sensitivity. These advancements enable researchers to obtain more accurate and detailed information about biological processes, disease mechanisms, and treatment responses, driving the growth of the preclinical imaging market.
Opportunity
- Increasing Adoption of Imaging Systems for Preclinical Purpose
The pharmaceutical and biotechnology industries are continually searching for novel drug candidates to address unmet medical needs. Preclinical imaging allows for a more comprehensive understanding of potential drug candidates by visualizing their effects on living organisms. This helps in identifying promising candidates and eliminating those with unfavorable characteristics earlier in the drug development process, saving time and resources. The shift toward personalized medicine requires a more thorough understanding of individual patients' conditions. Preclinical imaging can be used to assess disease heterogeneity and tailor treatment approaches, leading to more effective therapies.
Restraint / Challenge
- Stringent Regulatory Framework for Product Approval
Regulatory bodies around the world have established strict guidelines and requirements for the approval of preclinical imaging products, which can create barriers for companies in the market and is a significant restraint factor on the growth of the Asia-Pacific preclinical imaging market.
The regulatory process for preclinical imaging products is a time-consuming and expensive. Companies conduct comprehensive studies to demonstrate the safety and efficacy of their products, which involves significant investment in research and development. In addition, the regulatory submission process requires extensive documentation, data analysis, and interaction with regulatory authorities, all of which add to the time and cost burden.
Recent Developments
- In November 2022, Bruker announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. This helped the organization develop more revenue
- In May 2022, FUJIFILM Corporation announced the launch of Vevo F2, the world’s first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 features HD image processing technology and introduces a completely new signal pathway – from transducer to display screen. This enabled better image clarity, and when combined with multi-line processing, delivers significantly improved frame rates over earlier generation platforms
Asia-Pacific Preclinical Imaging Market Scope
The Asia-Pacific preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Systems
- Services
On the basis of product, the market is segmented into systems, and services.
Reagents
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents.
Application
- Research and Development
- Drug Discovery
- Bio-Distribution
- Cancer Cell Detection
- Bio-Markers
- Others
On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others.
End User
- Contract Research Organization
- Pharmaceutical & Biotech Companies
- Academic & Government Research Institutes
- Diagnostics Center
- Others
On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others.
Asia-Pacific Preclinical Imaging Market Regional Analysis/Insights
The Asia-Pacific preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user.
The countries covered in this market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific.
China is expected to dominate the market due to growing demand for imaging devices. China is the fastest growing country in the market with the largest market share due to rising technological advancements.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from regional brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Preclinical Imaging Market Share Analysis
The preclinical imaging market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Français Certains des principaux acteurs du marché opérant sur le marché de l'imagerie préclinique de la région Asie-Pacifique sont PerkinElmer Inc., FUJIFILM Visualsonics, Inc (une filiale de FUJIFILM Corporation), Bruker, Hologic, Inc., ZEISS Group, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd., LI-COR, Inc., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, AI4R et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC PRECLINICAL IMAGING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FIRCES
4.3 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
5.1 REGULATORY SCENARIO IN AUSTRALIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF IMAGING
6.1.2 INCREASING NUMBER OF INVESTMENTS AND FUNDING IN RESEARCH AND DEVELOPMENT
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY FRAMEWORK FOR PRODUCT APPROVAL
6.2.2 HIGH INSTALLATION AND OPERATIONAL COST OF PRECLINICAL IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 INCREASING ADOPTION OF IMAGING SYSTEMS FOR PRECLINICAL PURPOSES
6.3.2 GROWING DEMAND FOR NON-INVASIVE SMALL-ANIMAL IMAGING METHODS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS FOR THE EFFECTIVE UTILIZATION OF PRECLINICAL IMAGING SYSTEMS
6.4.2 INTEGRATION OF IMAGING DEVICES WITH OTHER TECHNOLOGIES
7 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 SYSTEMS
7.2.1 OPTICAL IMAGING SYSTEMS
7.2.1.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS
7.2.1.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS
7.2.1.3 OPTICAL + X-RAY/OPTICAL + CT
7.2.2 PRECLINICAL NUCLEAR IMAGING SYSTEMS
7.2.2.1 MICRO-POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS
7.2.2.2 MICRO-SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SYSTEMS
7.2.2.3 TRIPRODUCT (SPECT/PET/CT) SYSTEMS
7.2.3 MICRO-MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
7.2.4 MICRO-COMPUTED TOMOGRAPHY (CT) SYSTEMS
7.2.5 MICRO-ULTRASOUND SYSTEMS
7.2.6 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS
7.2.7 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS
7.2.8 MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI)
7.3 SERVICES
8 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY REAGENTS
8.1 OVERVIEW
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS
8.2.1 BIOLUMINESCENT IMAGING REAGENTS
8.2.2 FLUORESCENT IMAGING REAGENTS
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS
8.3.1 PRECLINICAL PET TRACERS
8.3.2 PRECLINICAL SPECT PROBES
8.4 PRECLINICAL MRI CONTRAST AGENTS
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.2 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.3 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS
8.6 PRECLINICAL CT CONTRAST AGENTS
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.3 GOLD NANOPARTICLES
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS
9 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 RESEARCH AND DEVELOPMENT
9.3 DRUG DISCOVERY
9.4 BIO-DISTRIBUTION
9.5 CANCER CELL DETECTION
9.6 BIO-MARKERS
9.7 OTHERS
10 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL & BIOTECH COMPANIES
10.4 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
10.5 DIAGNOSTICS CENTER
10.6 OTHERS
11 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY COUNTRY
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 SOUTH KOREA
11.1.4 INDIA
11.1.5 AUSTRALIA
11.1.6 SINGAPORE
11.1.7 THAILAND
11.1.8 MALAYSIA
11.1.9 INDONESIA
11.1.10 PHILIPPINES
11.1.11 RSET OF ASIA PACIFIC
12 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 PERKINELMER INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 FUJIFILM VISUALSONICS, INC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 HOLOGIC, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BRUKER
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 ZEISS GROUP
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ADVANCED MOLECULAR VISION, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 AGILENT TECHNOLOGIES, INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 AI4R
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BERTHOLD TECHNOLOGIES GMBH & CO.KG
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 HAMAMATSU PHOTONICS K.K.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 IVIM TECHNOLOGY CORP.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 LI-COR, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 MEDISO LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILABS B.V.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MR SOLUTIONS
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 PHOTON ETC
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 TRIFOIL IMAGING
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 VIEWORKS CO., LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 13 CHINA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 14 CHINA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 15 CHINA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 16 CHINA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 17 CHINA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 18 CHINA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 19 CHINA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 20 CHINA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 21 CHINA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 22 CHINA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 23 CHINA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 24 CHINA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 25 CHINA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 26 CHINA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 27 CHINA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 28 CHINA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 29 CHINA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 30 CHINA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 31 CHINA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 32 CHINA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 33 CHINA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 34 CHINA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 35 CHINA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 36 CHINA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 37 CHINA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 38 CHINA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 39 CHINA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 40 JAPAN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 41 JAPAN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 42 JAPAN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 43 JAPAN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 44 JAPAN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 45 JAPAN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 46 JAPAN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 47 JAPAN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 48 JAPAN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 49 JAPAN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 50 JAPAN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 51 JAPAN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 52 JAPAN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 53 JAPAN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 54 JAPAN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 55 JAPAN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 56 JAPAN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 57 JAPAN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 58 JAPAN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 59 JAPAN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 60 JAPAN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 61 JAPAN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 62 JAPAN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 63 JAPAN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 64 JAPAN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 65 JAPAN PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 66 JAPAN PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 67 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 68 SOUTH KOREA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 69 SOUTH KOREA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 70 SOUTH KOREA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 71 SOUTH KOREA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 72 SOUTH KOREA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 73 SOUTH KOREA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 74 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 75 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 76 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 77 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 78 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 79 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 80 SOUTH KOREA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 81 SOUTH KOREA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 82 SOUTH KOREA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 83 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 84 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 85 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 86 SOUTH KOREA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 87 SOUTH KOREA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 88 SOUTH KOREA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 89 SOUTH KOREA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 90 SOUTH KOREA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 91 SOUTH KOREA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 92 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 93 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 94 INDIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 95 INDIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 96 INDIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 97 INDIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 98 INDIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 99 INDIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 100 INDIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 101 INDIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 102 INDIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 103 INDIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 104 INDIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 105 INDIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 106 INDIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 107 INDIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 108 INDIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 109 INDIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 110 INDIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 111 INDIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 112 INDIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 113 INDIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 114 INDIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 115 INDIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 116 INDIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 117 INDIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 118 INDIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 119 INDIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 120 INDIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 121 AUSTRALIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 122 AUSTRALIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 123 AUSTRALIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 124 AUSTRALIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 125 AUSTRALIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 126 AUSTRALIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 127 AUSTRALIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 128 AUSTRALIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 129 AUSTRALIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 130 AUSTRALIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 131 AUSTRALIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 132 AUSTRALIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 133 AUSTRALIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 134 AUSTRALIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 135 AUSTRALIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 136 AUSTRALIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 137 AUSTRALIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 138 AUSTRALIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 139 AUSTRALIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 140 AUSTRALIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 141 AUSTRALIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 142 AUSTRALIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 143 AUSTRALIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 144 AUSTRALIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 145 AUSTRALIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 146 AUSTRALIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 147 AUSTRALIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 148 SINGAPORE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 149 SINGAPORE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 150 SINGAPORE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 151 SINGAPORE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 152 SINGAPORE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 153 SINGAPORE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 154 SINGAPORE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 155 SINGAPORE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 156 SINGAPORE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 157 SINGAPORE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 158 SINGAPORE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 159 SINGAPORE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 160 SINGAPORE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 161 SINGAPORE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 162 SINGAPORE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 163 SINGAPORE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 164 SINGAPORE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 165 SINGAPORE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 166 SINGAPORE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 167 SINGAPORE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 168 SINGAPORE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 169 SINGAPORE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 170 SINGAPORE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 171 SINGAPORE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 172 SINGAPORE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 173 SINGAPORE PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 174 SINGAPORE PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 175 THAILAND PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 176 THAILAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 177 THAILAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 178 THAILAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 179 THAILAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 180 THAILAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 181 THAILAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 182 THAILAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 183 THAILAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 184 THAILAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 185 THAILAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 186 THAILAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 187 THAILAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 188 THAILAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 189 THAILAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 190 THAILAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 191 THAILAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 192 THAILAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 193 THAILAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 194 THAILAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 195 THAILAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 196 THAILAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 197 THAILAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 198 THAILAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 199 THAILAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 200 THAILAND PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 201 THAILAND PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 202 MALAYSIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 203 MALAYSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 204 MALAYSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 205 MALAYSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 206 MALAYSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 207 MALAYSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 208 MALAYSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 MALAYSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 210 MALAYSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 211 MALAYSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 212 MALAYSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 213 MALAYSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 214 MALAYSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 215 MALAYSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 216 MALAYSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 217 MALAYSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 218 MALAYSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 219 MALAYSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 220 MALAYSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 221 MALAYSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 222 MALAYSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 223 MALAYSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 224 MALAYSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 225 MALAYSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 226 MALAYSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 227 MALAYSIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 228 MALAYSIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 229 INDONESIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 230 INDONESIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 231 INDONESIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 232 INDONESIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 233 INDONESIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 234 INDONESIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 235 INDONESIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 236 INDONESIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 237 INDONESIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 238 INDONESIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 239 INDONESIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 240 INDONESIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 241 INDONESIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 242 INDONESIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 243 INDONESIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 244 INDONESIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 245 INDONESIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 246 INDONESIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 247 INDONESIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 248 INDONESIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 249 INDONESIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 250 INDONESIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 251 INDONESIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 252 INDONESIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 253 INDONESIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 254 INDONESIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 INDONESIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 256 PHILIPPINES PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 257 PHILIPPINES SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 258 PHILIPPINES SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 259 PHILIPPINES SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 260 PHILIPPINES OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 261 PHILIPPINES OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 262 PHILIPPINES OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 263 PHILIPPINES PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 264 PHILIPPINES PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 265 PHILIPPINES PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 266 PHILIPPINES PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 267 PHILIPPINES PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 268 PHILIPPINES PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 269 PHILIPPINES PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 270 PHILIPPINES PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 271 PHILIPPINES PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 272 PHILIPPINES PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 273 PHILIPPINES PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 274 PHILIPPINES PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 275 PHILIPPINES PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 276 PHILIPPINES PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 277 PHILIPPINES PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 278 PHILIPPINES PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 279 PHILIPPINES PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 280 PHILIPPINES PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 281 PHILIPPINES PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 282 PHILIPPINES PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 283 REST OF ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF CHRONIC DISORDERS AND ADVANCEMENTS IN IMAGING TECHNIQUES ARE DRIVING THE GROWTH OF THE ASIA-PACIFIC PRECLINICAL IMAGING MARKET FROM 2023 TO 2030
FIGURE 12 SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC PRECLINICAL IMAGING MARKET
FIGURE 14 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, 2022
FIGURE 15 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, 2023-2030 (USD THOUSAND)
FIGURE 16 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 17 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, 2022
FIGURE 19 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, 2023-2030 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, CAGR (2023-2030)
FIGURE 21 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, 2022
FIGURE 23 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, 2022
FIGURE 27 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: SNAPSHOT (2022)
FIGURE 31 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
